Chimera Researc...'s  Instablog

Chimera Research Group
Send Message
The founding members of Chimera Research Group have over 50 years of combined experience in the biotech and pharmaceutical sector. Their experience includes work at Investment Banks, Hedge Funds, Pharmaceutical Companies, top-tier Universities, and the U.S. Food and Drug Administration (FDA).... More
My company:
Chimera Research Group
My blog:
Chimera Blog
My book:
The Biotech Trader Handbook (2nd Edition)
  • Why is Exelixis Shrinking? 0 comments
    Mar 4, 2011 8:17 PM
    Exelixis has skyrocked over 300% from its August lows to its current price of about $12 on positive news for its lead compound, cabozantinib in prostate cancer, giving it a market cap of about $1.3 billioin. It is now positioned to file an NDA for its initial indication of medullary thyroid cancer (MTC) in the latter half of this year and initiate the first pivotal trial in prostate during the same period.
    From a height of close to 800 employees just a couple years ago, Exelixis is now down to a mere 240 after a large restructuring in 2010. This number will drift down to 150 soon. A company that once boasted of its enormous pipeline is now focusing all its efforts on a single compound. It has either stopped research on its early stage candidates or shifted work to partners.
    The days of generating multiple INDs per year are probably over. That business model is no longer sustainable with its heavy costs, lack of return. CEO Mike Morrissey even mentioned equipment is now being auctioned off.
    Still, why is the company still shrinking? At this point, when drug makers get close to launch, they typically begin building a commercialization team. Is Dr. Morrissey prepping the company for a sale?
Back To Chimera Research Group's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers


  • $CELG $CELG Abraxane ph 3 pancreatic cancer trial shows stat sig improvemnt in overall survival! Suggested this back in June for subscribrs
    Nov 10, 2012
  • We are big believers in $PCYC, $MDVN, $INCY, $SGEN and more.
    Jul 10, 2012
  • $CHTP: 700 call contracts traded today. speculative interest returning...?
    Aug 10, 2010
More »

Latest Comments

Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.